These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

473 related items for PubMed ID: 25692608

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Early-Onset Efficacy and Safety Pilot Study of Amphetamine Extended-Release Oral Suspension in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder.
    Childress AC, Kando JC, King TR, Pardo A, Herman BK.
    J Child Adolesc Psychopharmacol; 2019 Feb; 29(1):2-8. PubMed ID: 30575407
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder.
    Wigal SB, Childress A, Berry SA, Belden H, Walters F, Chappell P, Sherman N, Orazem J, Palumbo D.
    J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):690-699. PubMed ID: 28557548
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting.
    Childress AC, Kollins SH, Cutler AJ, Marraffino A, Sikes CR.
    J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):66-74. PubMed ID: 27183299
    [Abstract] [Full Text] [Related]

  • 7. NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study.
    Wigal SB, Childress AC, Belden HW, Berry SA.
    J Child Adolesc Psychopharmacol; 2013 Feb; 23(1):3-10. PubMed ID: 23289899
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study.
    Biederman J, Boellner SW, Childress A, Lopez FA, Krishnan S, Zhang Y.
    Biol Psychiatry; 2007 Nov 01; 62(9):970-6. PubMed ID: 17631866
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder: Effect Size Across the Day.
    Faraone SV, Childress AC, Gomeni R, Rafla E, Kando JC, Dansie L, Naik P, Pardo A.
    J Child Adolesc Psychopharmacol; 2023 Feb 01; 33(1):14-19. PubMed ID: 36730749
    [Abstract] [Full Text] [Related]

  • 11. A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings.
    Childress AC, Cutler AJ, Marraffino A, McDonnell MA, Turnbow JM, Brams M, DeSousa NJ, Incledon B, Sallee FR, Wigal SB.
    J Child Adolesc Psychopharmacol; 2020 Feb 01; 30(1):2-14. PubMed ID: 31464511
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study.
    Babcock T, Dirks B, Adeyi B, Scheckner B.
    BMC Pharmacol Toxicol; 2012 Dec 19; 13():18. PubMed ID: 23254273
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy and Safety of Multilayer, Extended-Release Methylphenidate (PRC-063) in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder: A Laboratory Classroom Study.
    Childress AC, Brams MN, Cutler AJ, Donnelly GAE, Bhaskar S.
    J Child Adolesc Psychopharmacol; 2020 Dec 19; 30(10):580-589. PubMed ID: 33090921
    [Abstract] [Full Text] [Related]

  • 15. Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
    Wigal T, Brams M, Gasior M, Gao J, Giblin J.
    Postgrad Med; 2011 Mar 19; 123(2):169-76. PubMed ID: 21474905
    [Abstract] [Full Text] [Related]

  • 16. A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect.
    Brams M, Muniz R, Childress A, Giblin J, Mao A, Turnbow J, Borrello M, McCague K, Lopez FA, Silva R.
    CNS Drugs; 2008 Mar 19; 22(8):693-704. PubMed ID: 18601306
    [Abstract] [Full Text] [Related]

  • 17. A randomized, double-blind study of SHP465 mixed amphetamine salts extended-release in adults with ADHD using a simulated adult workplace design.
    Wigal T, Brams M, Frick G, Yan B, Madhoo M.
    Postgrad Med; 2018 Jun 19; 130(5):481-493. PubMed ID: 29809075
    [Abstract] [Full Text] [Related]

  • 18. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
    Najib J.
    Clin Ther; 2009 Jan 19; 31(1):142-76. PubMed ID: 19243715
    [Abstract] [Full Text] [Related]

  • 19. A randomized placebo-controlled double-blind study evaluating the time course of response to methylphenidate hydrochloride extended-release capsules in children with attention-deficit/hyperactivity disorder.
    Wigal SB, Greenhill LL, Nordbrock E, Connor DF, Kollins SH, Adjei A, Childress A, Stehli A, Kupper RJ.
    J Child Adolesc Psychopharmacol; 2014 Dec 19; 24(10):562-9. PubMed ID: 25470572
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.